94 citations · 126 across the 5 of their papers we have counts for
5 papers
DEMO: Dose Exploration, Monitoring, and Optimization Using a Biological Mediator for Clinical Outcomes
Cheng-Han Yang, Peter F. Thall, Ruitao Lin
Phase 1-2 designs provide a methodological advance over phase 1 designs for dose finding by using both clinical response and toxicity. A phase 1-2 trial still may fail to select a…
A Bayesian Feature Allocation Model for Identification of Cell Subpopulations Using Cytometry Data
Arthur Lui, Juhee Lee, Peter F. Thall +3
A Bayesian feature allocation model (FAM) is presented for identifying cell subpopulations based on multiple samples of cell surface or intracellular marker expression level data o…
A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling
Yanxun Xu, Peter F. Thall, Peter Mueller +1
We propose a Bayesian nonparametric utility-based group sequential design for a randomized clinical trial to compare a gel sealant to standard care for resolving air leaks after pu…
Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times
Yanxun Xu, Peter Mueller, Abdus S. Wahed +1
Dynamic treatment regimes in oncology and other disease areas often can be characterized by an alternating sequence of treatments or other actions and transition times between dise…
Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials
Peter F. Thall
An early phase clinical trial is the first step in evaluating the effects in humans of a potential new anti-disease agent or combination of agents. Usually called "phase I" or "pha…